{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T01:37:58Z","timestamp":1794620278773,"version":"4.9.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T00:00:00Z","timestamp":1694044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T00:00:00Z","timestamp":1694044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prediabetes and diabetes involve alterations in glucose homeostasis, including increased fasting blood glucose and impaired glucose tolerance. Berberine has been identified as a potential regulator of glucose homeostasis with implications on the management of type 2 diabetes mellitus (DM). Given a paucity of data on berberine in prediabetes, evaluation of its effect in individuals with prediabetes may prove clinically valuable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The present pilot study aimed to investigate the effect of daily oral berberine on markers of glycemic control and insulin resistance among individuals with prediabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A randomized, double-blinded, placebo-controlled trial was conducted for 12 weeks among 34 individuals with prediabetes as defined by the American Diabetes Association (fasting plasma glucose (FPG) between 5.6 and 6.9 mmol\/L, glycosylated hemoglobin (HbA\n                      <jats:sub>1c<\/jats:sub>\n                      ) between 5.7% and 6.4%, or 2-hour 75-gram oral glucose tolerance test (2\u00a0h-OGTT) between 7.8 and 11.1 mmol\/L). HIMABERB\u00ae 500\u00a0mg was given three times daily to the treatment group, and placebo was administered three times daily to the control group. Glycemic control markers and physical parameters were evaluated for both groups on days 0, 28, 56, and 84. The glycemic control markers assessed included FPG, fasting insulin (FI), 2\u00a0h-OGTT, HbA\n                      <jats:sub>1c<\/jats:sub>\n                      , and homeostatic model assessment-insulin resistance (HOMA-IR). The observed outcomes were analyzed using independent t-test statistics to determine the significance of differences over time after treatment initiation and between treatment and control groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Significant decreases in all markers of glycemic control were observed in the treatment group at intermediate time points and the endpoint of the study compared to baseline levels and to the control group. For the treatment group, FPG decreased from 6.75\u2009\u00b1\u20090.23 mmol\/L to 5.33\u2009\u00b1\u20090.28 mmol\/L, FI from 9.81\u2009\u00b1\u20090.36 to 7.88\u2009\u00b1\u20090.52 mmol\/L, 2\u00a0h-OGTT from 10.44\u2009\u00b1\u20090.52 to 8.12\u2009\u00b1\u20090.40 mmol\/L, HbA\n                      <jats:sub>1c<\/jats:sub>\n                      from 6.40% \u00b1 0.20\u20135.43% \u00b1 0.21%, and HOMA-IR from 3.61\u2009\u00b1\u20090.31 to 2.41\u2009\u00b1\u20090.14. The decreases in glycemic control markers compared to the control group were clinically and statistically significant (p&lt;10\n                      <jats:sup>\u2212\u20095<\/jats:sup>\n                      ). No severe adverse effects, kidney or liver toxicity were detected.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>After 12 weeks, berberine (HIMABERB\u00ae) intervention in individuals with prediabetes significantly reduced glycemic control markers, with mean FPG and 2\u00a0h-OTGG being reduced to below prediabetic thresholds, supporting the investigation of the use of HIMABERB\u00ae for delaying progression to diabetes mellitus.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/ctri.nic.in\">http:\/\/ctri.nic.in<\/jats:ext-link>\n                      <jats:bold>(CTRI\/2021\/12\/038751) (20\/12\/2021)<\/jats:bold>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12902-023-01442-y","type":"journal-article","created":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T05:02:10Z","timestamp":1694062930000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Efficacy and safety of HIMABERB\u00ae Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial"],"prefix":"10.1186","volume":"23","author":[{"given":"Antarmayee","family":"Panigrahi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susant","family":"Mohanty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,7]]},"reference":[{"key":"1442_CR1","unstructured":"\u201cFacts. & figures.\u201d https:\/\/idf.org\/aboutdiabetes\/what-is-diabetes\/facts-figures.html (accessed Jul. 12, 2022)."},{"key":"1442_CR2","unstructured":"\u201cIDF Diabetes Atlas. 2021 | IDF Diabetes Atlas.\u201d https:\/\/diabetesatlas.org\/atlas\/tenth-edition\/ (accessed May 11, 2022)."},{"key":"1442_CR3","doi-asserted-by":"publisher","unstructured":"Association AD, Supplement_1. S15\u2013S33, Jan. 2021, doi: https:\/\/doi.org\/10.2337\/DC21-S002.","DOI":"10.2337\/DC21-S002"},{"key":"1442_CR4","doi-asserted-by":"publisher","unstructured":"Nichols GA, Hillier TA, Brown JB. \u201cNormal Fasting Plasma Glucose and Risk of Type 2 Diabetes Diagnosis,\u201d Am. J. Med, vol.\u00a0121, no. 6, pp.\u00a0519\u2013524, Jun. 2008, https:\/\/doi.org\/10.1016\/J.AMJMED.2008.02.026.","DOI":"10.1016\/J.AMJMED.2008.02.026"},{"key":"1442_CR5","unstructured":"\u201cNational Diabetes Statistics Report | Diabetes | CDC. \u201d https:\/\/www.cdc.gov\/diabetes\/data\/statistics-report\/index.html (accessed May 11, 2022)."},{"key":"1442_CR6","doi-asserted-by":"publisher","unstructured":"Association AD, Supplement_1. S34\u20139, Jan. 2021, doi: https:\/\/doi.org\/10.2337\/DC21-S003.","DOI":"10.2337\/DC21-S003"},{"key":"1442_CR7","doi-asserted-by":"publisher","unstructured":"Ziegenfuss TN, Hofheins JE, Mendel RW, Landis J, Anderson RA. \u201cEffects of a Water-Soluble Cinnamon Extract on Body Composition and Features of the Metabolic Syndrome in Pre-Diabetic Men and Women,\u201d J. Int. Soc. Sport. Nutr 2006 32, vol.\u00a03, no. 2, pp.\u00a01\u20139, Dec. 2006, https:\/\/doi.org\/10.1186\/1550-2783-3-2-45.","DOI":"10.1186\/1550-2783-3-2-45"},{"key":"1442_CR8","doi-asserted-by":"publisher","unstructured":"Gaddam A, Galla C, Thummisetti S, Marikanty RK, Palanisamy UD, Rao PV. \u201cRole of Fenugreek in the prevention of type 2 diabetes mellitus in prediabetes,\u201d J. Diabetes Metab. Disord, vol.\u00a014, no. 1, pp.\u00a01\u201310, Oct. 2015, https:\/\/doi.org\/10.1186\/S40200-015-0208-4\/TABLES\/5.","DOI":"10.1186\/S40200-015-0208-4\/TABLES\/5"},{"key":"1442_CR9","doi-asserted-by":"publisher","unstructured":"Afifi M, Alkaladi A, Abomughaid MM, Abdelazim AM. Nanocurcumin improved glucose metabolism in streptozotocin-induced diabetic rats: a comparison study with gliclazide. Environ Sci Pollut Res. Jul. 2020;27:25271\u20137. https:\/\/doi.org\/10.1007\/S11356-020-08941-8\/FIGURES\/2.","DOI":"10.1007\/S11356-020-08941-8\/FIGURES\/2"},{"key":"1442_CR10","doi-asserted-by":"publisher","unstructured":"Jamshidi N, Costa CD, Cohen M. \u201cHolybasil (tulsi) lowers fasting glucose and improves lipid profile in adults with metabolic disease: A meta-analysis of randomized clinical trials,\u201d J. Funct. Foods, vol.\u00a045, pp.\u00a047\u201357, Jun. 2018, https:\/\/doi.org\/10.1016\/J.JFF.2018.03.030.","DOI":"10.1016\/J.JFF.2018.03.030"},{"key":"1442_CR11","doi-asserted-by":"publisher","unstructured":"Choi MS, et al. The beneficial effect of soybean (Glycine max (L.) Merr.) Leaf extracts in adults with prediabetes: a randomized placebo controlled trial. Food Funct. Jun. 2014;5(7):1621\u201330. https:\/\/doi.org\/10.1039\/C4FO00199K.","DOI":"10.1039\/C4FO00199K"},{"key":"1442_CR12","doi-asserted-by":"publisher","unstructured":"Sen S, Chakraborty R. \u201cRevival, modernization and integration of Indian traditional herbal medicine in clinical practice: Importance, challenges and future,\u201d J. Tradit. Complement. Med, vol.\u00a07, no. 2, pp.\u00a0234\u2013244, Apr. 2017, https:\/\/doi.org\/10.1016\/J.JTCME.2016.05.006.","DOI":"10.1016\/J.JTCME.2016.05.006"},{"key":"1442_CR13","doi-asserted-by":"publisher","unstructured":"Wei X, Zhu L, Wang C. \u201cEfficacy and Safety of Berberine in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis,\u201d Chinese Herb. Med, vol.\u00a07, no. 4, pp.\u00a0344\u2013353, Nov. 2015, https:\/\/doi.org\/10.1016\/S1674-6384(15)60063-6.","DOI":"10.1016\/S1674-6384(15)60063-6"},{"key":"1442_CR14","doi-asserted-by":"publisher","unstructured":"Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. May 2008;57(5):712\u20137. https:\/\/doi.org\/10.1016\/j.metabol.2008.01.013.","DOI":"10.1016\/j.metabol.2008.01.013"},{"key":"1442_CR15","doi-asserted-by":"publisher","unstructured":"Wang HJ, Chiang BH. Anti-diabetic effect of a traditional chinese medicine formula. Food Funct. Oct. 2012;3(11):1161\u20139. https:\/\/doi.org\/10.1039\/C2FO30139C.","DOI":"10.1039\/C2FO30139C"},{"issue":"6","key":"1442_CR16","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1055\/S-0032-1328321","volume":"79","author":"H Dong","year":"2013","unstructured":"Dong H, Zhao Y, Zhao L, Lu F. The effects of berberine on blood lipids: a systemic review and meta-analysis of randomized controlled trials. Planta Med. 2013;79(6):437\u201346. https:\/\/doi.org\/10.1055\/S-0032-1328321.","journal-title":"Planta Med"},{"key":"1442_CR17","doi-asserted-by":"publisher","unstructured":"DeFronzo RA, Abdul-Ghani M. \u201cAssessment and Treatment of Cardiovascular Risk in Prediabetes: Impaired Glucose Tolerance and Impaired Fasting Glucose,\u201d Am. J. Cardiol, vol.\u00a0108, no. 3, pp.\u00a03B-24B, Aug. 2011, https:\/\/doi.org\/10.1016\/J.AMJCARD.2011.03.013.","DOI":"10.1016\/J.AMJCARD.2011.03.013"},{"key":"1442_CR18","doi-asserted-by":"publisher","unstructured":"Tab\u00e1k AG, Herder C, Rathmann W, Brunner EJ, Kivim\u00e4ki M. Prediabetes: a high-risk state for developingdiabetes. Lancet. Jun. 2012;379:2279. https:\/\/doi.org\/10.1016\/S0140-6736(12)60283-9.","DOI":"10.1016\/S0140-6736(12)60283-9"},{"key":"1442_CR19","doi-asserted-by":"publisher","unstructured":"Kantor ED, Rehm CD, Du M, White E, Giovannucci EL. Trends in Dietary supplement use among US adults from 1999\u20132012. JAMA. Oct. 2016;316:1464\u201374. https:\/\/doi.org\/10.1001\/JAMA.2016.14403.","DOI":"10.1001\/JAMA.2016.14403"},{"key":"1442_CR20","doi-asserted-by":"publisher","unstructured":"xia Ni Y et al. \u201cTherapeutic effect of berberine on 60 patients with non-insulin dependent diabetes mellitus and experimental research,\u201d Chinese J. Integr. Tradit. West. Med 1995 12, vol.\u00a01, no. 2, pp.\u00a091\u201395, 1995, https:\/\/doi.org\/10.1007\/BF02942756.","DOI":"10.1007\/BF02942756"},{"key":"1442_CR21","doi-asserted-by":"publisher","unstructured":"Yin J, Xing H, Ye J. Efficacy of Berberine in patients with type 2 diabetes. Metabolism. May 2008;57(5):712. https:\/\/doi.org\/10.1016\/J.METABOL.2008.01.013.","DOI":"10.1016\/J.METABOL.2008.01.013"},{"key":"1442_CR22","doi-asserted-by":"publisher","unstructured":"Lee YS et al. \u201cBerberine, a Natural Plant Product, Activates AMP-Activated Protein Kinase With Beneficial Metabolic Effects in Diabetic and Insulin-Resistant States,\u201d Diabetes, vol.\u00a055, no. 8, pp.\u00a02256\u20132264, Aug. 2006, https:\/\/doi.org\/10.2337\/DB06-0006.","DOI":"10.2337\/DB06-0006"},{"key":"1442_CR23","doi-asserted-by":"publisher","unstructured":"Jiang Q, et al. Berberine attenuates lipopolysaccharide-induced extracelluar matrix accumulation and inflammation in rat mesangial cells: involvement of NF-\u03baB signaling pathway. Mol Cell Endocrinol. Jan. 2011;1:34\u201340. https:\/\/doi.org\/10.1016\/J.MCE.2010.07.023.","DOI":"10.1016\/J.MCE.2010.07.023"},{"key":"1442_CR24","doi-asserted-by":"publisher","unstructured":"Wang L et al. \u201cBerberine and Prediabetes: A Clinical Observational Study,\u201d J. Diabetes Mellit, vol.\u00a010, no. 4, pp.\u00a0209\u2013221, Sep. 2020, https:\/\/doi.org\/10.4236\/JDM.2020.104017.","DOI":"10.4236\/JDM.2020.104017"},{"issue":"7","key":"1442_CR25","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1210\/jc.2007-2404","volume":"93","author":"Y Zhang","year":"2008","unstructured":"Zhang Y, et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab. 2008;93(7):2559\u201365. https:\/\/doi.org\/10.1210\/jc.2007-2404.","journal-title":"J Clin Endocrinol Metab"},{"key":"1442_CR26","doi-asserted-by":"publisher","unstructured":"Zhou L et al. \u201cBerberine stimulates glucose transport through a mechanism distinct from insulin,\u201d Metabolism, vol.\u00a056, no. 3, pp.\u00a0405\u2013412, Mar. 2007, https:\/\/doi.org\/10.1016\/j.metabol.2006.10.025.","DOI":"10.1016\/j.metabol.2006.10.025"},{"key":"1442_CR27","doi-asserted-by":"publisher","unstructured":"Li J, et al. Hepatoprotective effects of berberine on liver fibrosis via activation of AMP-activated protein kinase. Life Sci. Mar. 2014;98(1):24\u201330. https:\/\/doi.org\/10.1016\/j.lfs.2013.12.211.","DOI":"10.1016\/j.lfs.2013.12.211"},{"key":"1442_CR28","doi-asserted-by":"publisher","unstructured":"Zhang H, et al. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism. Feb. 2010;59(2):285\u201392. https:\/\/doi.org\/10.1016\/j.metabol.2009.07.029.","DOI":"10.1016\/j.metabol.2009.07.029"},{"issue":"11","key":"1442_CR29","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1053\/meta.2002.34715","volume":"51","author":"J Yin","year":"2002","unstructured":"Yin J, et al. Effects of berberine on glucose metabolism in vitro. \u201d Metabolism. 2002;51(11):1439\u201343. https:\/\/doi.org\/10.1053\/meta.2002.34715.","journal-title":"\u201d Metabolism"},{"issue":"1","key":"1442_CR30","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1507\/ENDOCRJ.EJ18-0109","volume":"66","author":"Y Liang","year":"2019","unstructured":"Liang Y, et al. Effects of berberine on blood glucose in patients with type 2 diabetes mellitus: a systematic literature review and a meta-analysis. Endocr J. 2019;66(1):51\u201363. https:\/\/doi.org\/10.1507\/ENDOCRJ.EJ18-0109.","journal-title":"Endocr J"},{"key":"1442_CR31","doi-asserted-by":"publisher","unstructured":"Feinberg T et al. \u201cPolyherbal dietary supplementation for prediabetic adults: study protocol for a randomized controlled trial,\u201d Trials 2019 201, vol.\u00a020, no. 1, pp.\u00a01\u201313, Jan. 2019, https:\/\/doi.org\/10.1186\/S13063-018-3032-6.","DOI":"10.1186\/S13063-018-3032-6"},{"key":"1442_CR32","doi-asserted-by":"publisher","unstructured":"Dong H, Wang N, Zhao L, Lu F. \u201cBerberine in the treatment of type 2 diabetes mellitus: A systemic review and meta-analysis,\u201d Evidence-based Complement. Altern. Med, vol. 2012, 2012, https:\/\/doi.org\/10.1155\/2012\/591654.","DOI":"10.1155\/2012\/591654"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-023-01442-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-023-01442-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-023-01442-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T10:13:20Z","timestamp":1700216000000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-023-01442-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,7]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1442"],"URL":"https:\/\/doi.org\/10.1186\/s12902-023-01442-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2302156\/v1","asserted-by":"object"}]},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,7]]},"assertion":[{"value":"22 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No individual\u2019s data requring consent is presented in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Informed consent was given by all participants in this study. The work described was carried out by The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans. This study (approval no. SOA\/IDS\/IRB\/2021\u221210) was approved by the Institutional Ethical Committee (IEC), IMS & SUM Hospital, Siksha \u2019O\u2019 Anusandhan University, K\u22128 Kalinga Nagar. Bhubaneswar, Odisha\u221275003 (on May 17, 2021). The study protocol was registered at\n                      \n                      (CTRI\/2021\/12\/038751, December 20, 2021).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent and patient details"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"190"}}